Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15829806 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL9605414 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL2624407 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL20713626 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL24004406 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL17703268 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL24004415 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL20713629 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL20713675 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL13785546 | 1.00 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330807-A1 | NOVEL HYDROGEL CONJUGATES | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | L3MBTL1 4125/4885MAPT 3817/4885POLB 4429/4885 |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | L3MBTL1 4794/4885MAPT 1460/4885POLB 2760/4885 |
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | VEGFA, FLT4, FLT1 | L3MBTL1 4302/4885MAPT 3553/4885POLB 2684/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | L3MBTL1 2200/4885MAPT 3800/4885POLB 3885/4885 |
| US-20210330807-A1 | NOVEL HYDROGEL CONJUGATES | CD44, MSN, TBCA | L3MBTL1 3005/4885MAPT 1509/4885POLB 4425/4885 |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | VEGFA, FLT4, FLT1 | L3MBTL1 4302/4885MAPT 3553/4885POLB 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.